These results agree with a recent report demonstrating a significantly higher response rate to imatinib among patients with GIST containing exon 11 KIT mutations compared to those without such mutations (Heinrich et al, 2002a, 2002b). Here, KIT is linked to gastrointestinal stromal tumor.